219 related articles for article (PubMed ID: 8549036)
1. Rifampin drastically reduces plasma concentrations and effects of oral midazolam.
Backman JT; Olkkola KT; Neuvonen PJ
Clin Pharmacol Ther; 1996 Jan; 59(1):7-13. PubMed ID: 8549036
[TBL] [Abstract][Full Text] [Related]
2. Triazolam is ineffective in patients taking rifampin.
Villikka K; Kivistö KT; Backman JT; Olkkola KT; Neuvonen PJ
Clin Pharmacol Ther; 1997 Jan; 61(1):8-14. PubMed ID: 9024169
[TBL] [Abstract][Full Text] [Related]
3. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
Backman JT; Kivistö KT; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Mar; 54(1):53-8. PubMed ID: 9591931
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin.
Kivistö KT; Villikka K; Nyman L; Anttila M; Neuvonen PJ
Clin Pharmacol Ther; 1998 Dec; 64(6):648-54. PubMed ID: 9871429
[TBL] [Abstract][Full Text] [Related]
5. Azithromycin does not increase plasma concentrations of oral midazolam.
Backman JT; Olkkola KT; Neuvonen PJ
Int J Clin Pharmacol Ther; 1995 Jun; 33(6):356-9. PubMed ID: 7582388
[TBL] [Abstract][Full Text] [Related]
6. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
7. Effects of metronidazole on midazolam metabolism in vitro and in vivo.
Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Eur J Clin Pharmacol; 2000 Nov; 56(8):555-9. PubMed ID: 11151744
[TBL] [Abstract][Full Text] [Related]
8. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study.
Hamaoka N; Oda Y; Hase I; Mizutani K; Nakamoto T; Ishizaki T; Asada A
Clin Pharmacol Ther; 1999 Aug; 66(2):110-7. PubMed ID: 10460064
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
[TBL] [Abstract][Full Text] [Related]
10. Rifampin reduces plasma concentrations and effects of zolpidem.
Villikka K; Kivistö KT; Luurila H; Neuvonen PJ
Clin Pharmacol Ther; 1997 Dec; 62(6):629-34. PubMed ID: 9433391
[TBL] [Abstract][Full Text] [Related]
11. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam.
Ibrahim A; Karim A; Feldman J; Kharasch E
Anesth Analg; 2002 Sep; 95(3):667-73, table of contents. PubMed ID: 12198057
[TBL] [Abstract][Full Text] [Related]
12. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
[TBL] [Abstract][Full Text] [Related]
13. Concentrations and effects of zopiclone are greatly reduced by rifampicin.
Villikka K; Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
Br J Clin Pharmacol; 1997 May; 43(5):471-4. PubMed ID: 9159561
[TBL] [Abstract][Full Text] [Related]
14. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.
Palkama VJ; Ahonen J; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 1999 Jul; 66(1):33-9. PubMed ID: 10430107
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
Padhi D; Salfi M; Emery M
Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
[TBL] [Abstract][Full Text] [Related]
16. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics.
Gashaw I; Kirchheiner J; Goldammer M; Bauer S; Seidemann J; Zoller K; Mrozikiewicz PM; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Nov; 74(5):448-57. PubMed ID: 14586385
[TBL] [Abstract][Full Text] [Related]
18. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
Clin Pharmacol Ther; 1997 Sep; 62(3):348-54. PubMed ID: 9333111
[TBL] [Abstract][Full Text] [Related]
19. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.
Gurley B; Hubbard MA; Williams DK; Thaden J; Tong Y; Gentry WB; Breen P; Carrier DJ; Cheboyina S
J Clin Pharmacol; 2006 Feb; 46(2):201-13. PubMed ID: 16432272
[TBL] [Abstract][Full Text] [Related]
20. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron.
Villikka K; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1999 Apr; 65(4):377-81. PubMed ID: 10223773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
